C.R. Bard blows away sales and earnings expectations in Q1
April 25, 2014 by Arezu Sarvestani
Healthcare giant C.R. Bard posted major profit growth in its 1st quarter, beating Wall Street’s expectations with its adjusted per-share earnings.
The Murray Hill, N.J., company’s profits gained 63.6% year-over-year, and its adjusted EPS of $1.91 beat analysts’ consensus estimate by 6¢. Read more
Zimmer beats The Street, alters 2014 forecast on Biomet buy
April 24, 2014 by Arezu Sarvestani
Zimmer turned a lot of heads today with news of its $13.35 billion mega-offer for fellow orthopedics giant Biomet, with little love lost over a lowered per-share forecast for the rest of the year.
The company announced the Biomet buy in parallel with news of its latest quarter, in which sales rose 2% and profits gained about 1.3%. Zimmer’s adjusted Q1 earnings amounted to $1.50 per share, beating expectations by about 3¢. Read more
Vascular Solutions lowers 2014 forecast on higher legal fees
April 24, 2014 by Arezu Sarvestani
Vascular Solutions wasn’t making friends on Wall Street this week after the company missed expectations for Q1 and lowered its forecast for the rest of the year.
Even with a 31.7% boost in profits year-over-year, the Minneapolis company missed projections by 2¢. VASC shares dropped more than 5% after the company released its earnings on Tuesday, closing at $22.92 last night. Read more
Lombard Medical sinks on IPO day | MassDevice.com On Call
April 28, 2014 by Arezu Sarvestani
MASSDEVICE ON CALL — London medtech maker Lombard Medical Technologies had a lackluster 1st day on the Nasdaq stock exchange, with its new EVAR shares opening flat and losing 9% by the end of the day.
The EVAR stock opened at $11 and closed at $10 on Friday, marking another dim development for the company’s troubled IPO efforts. Read more
Edwards Lifesciences' Sapien sales grow 11.5% in Q1
April 25, 2014 by Arezu Sarvestani
Medtech giant Edwards Lifesciences posted Street-beating figures for its 1st quarter, driven largely by growth in its transcatheter heart valves.
Sales of its Sapien suite of valves grew 11.5% year-over-year, contributing to a 2.7% increase in adjusted per-share earnings, which beat analysts’ expectations by 7¢. Total revenues increased 5.3% during Q1, but fell just shy of analysts estimates. Read more
